ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [31] Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 1999 - 2001
  • [32] Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
    White, Maya N.
    Piper-Vallillo, Andrew J.
    Gardner, Rebecca M.
    Cunanan, Kristen
    Neal, Joel W.
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Chen, Thomas T.
    Sequist, Lecia, V
    Piotrowska, Zofia
    Wakelee, Heather A.
    CLINICAL LUNG CANCER, 2022, 23 (03) : E210 - E221
  • [33] Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
    Qian, Xiaoyu
    Guo, Xiaodan
    Li, Ting
    Hu, Wei
    Zhang, Lin
    Wu, Caisheng
    Ye, Feng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [34] Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
    Myall, Nathaniel J.
    Whisenant, Jennifer G.
    Neal, Joel W.
    Iams, Wade T.
    Reckamp, Karen L.
    York, Sally
    Berry, Lynne D.
    Shyr, Yu
    Horn, Leora
    Wakelee, Heather A.
    Padda, Sukhmani K.
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (02):
  • [35] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [36] A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases
    He, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S490 - S490
  • [37] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [38] Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors
    Nishino, Mizuki
    Lu, Junwei
    Hino, Takuya
    Vokes, Natalie I.
    Janne, Pasi A.
    Hatabu, Hiroto
    Johnson, Bruce E.
    JOURNAL OF THORACIC IMAGING, 2023, 38 (02) : 82 - 87
  • [39] Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
    Ruglioni, Martina
    Petrini, Iacopo
    Crucitta, Stefania
    Sbrana, Andrea
    Luculli, Giovanna Irene
    Gol, Leila Sadeghi
    Forte, Carola
    Chella, Antonio
    Rolfo, Christian
    Danesi, Romano
    Del Re, Marzia
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [40] Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
    Feng, W.
    Gu, W.
    Zhang, H.
    Lu, Y.
    Gu, W.
    Li, M.
    Yang, S.
    Zhang, J.
    Ye, Z.
    Lin, Q.
    Liang, Y.
    Chen, H.
    Cheng, Y.
    Yao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622
12345